JP2023525100A5 - - Google Patents

Info

Publication number
JP2023525100A5
JP2023525100A5 JP2022568601A JP2022568601A JP2023525100A5 JP 2023525100 A5 JP2023525100 A5 JP 2023525100A5 JP 2022568601 A JP2022568601 A JP 2022568601A JP 2022568601 A JP2022568601 A JP 2022568601A JP 2023525100 A5 JP2023525100 A5 JP 2023525100A5
Authority
JP
Japan
Prior art keywords
melanoma
pharmaceutically acceptable
use according
compound
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525100A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/054013 external-priority patent/WO2021229439A1/en
Publication of JP2023525100A publication Critical patent/JP2023525100A/ja
Publication of JP2023525100A5 publication Critical patent/JP2023525100A5/ja
Pending legal-status Critical Current

Links

JP2022568601A 2020-05-12 2021-05-11 Craf阻害剤を含む治療的組み合わせ Pending JP2023525100A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023470P 2020-05-12 2020-05-12
US63/023,470 2020-05-12
PCT/IB2021/054013 WO2021229439A1 (en) 2020-05-12 2021-05-11 Therapeutic combinations comprising a craf inhibitor

Publications (2)

Publication Number Publication Date
JP2023525100A JP2023525100A (ja) 2023-06-14
JP2023525100A5 true JP2023525100A5 (cg-RX-API-DMAC7.html) 2024-05-21

Family

ID=75954158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568601A Pending JP2023525100A (ja) 2020-05-12 2021-05-11 Craf阻害剤を含む治療的組み合わせ

Country Status (6)

Country Link
US (1) US20240000789A1 (cg-RX-API-DMAC7.html)
EP (1) EP4149472A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525100A (cg-RX-API-DMAC7.html)
CN (1) CN115551509A (cg-RX-API-DMAC7.html)
TW (1) TW202207942A (cg-RX-API-DMAC7.html)
WO (1) WO2021229439A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
TW202440128A (zh) * 2023-01-06 2024-10-16 美商艾瑞斯卡公司 Raf抑制劑及erk1/2及/或shp2抑制劑組合療法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
GB0719771D0 (en) * 2007-10-10 2007-11-21 Therapeutics Ltd E Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI839690B (zh) * 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
DK3063143T3 (en) 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
WO2017037587A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Combination of ribociclib and dabrafenib for treating or preventing cancer
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy
TW202023556A (zh) * 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
CA3123510A1 (en) * 2018-12-20 2020-06-25 Novartis Ag Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
TW202140029A (zh) * 2020-02-18 2021-11-01 瑞士商諾華公司 用於治療braf突變型nsclc的包含raf抑制劑之治療組合

Similar Documents

Publication Publication Date Title
Gogas et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
JP2024133475A5 (cg-RX-API-DMAC7.html)
JP2024133474A5 (cg-RX-API-DMAC7.html)
Cavallini et al. Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy
JP2018519340A5 (cg-RX-API-DMAC7.html)
JP2024516795A (ja) エベロリムスおよびアムセネストラントを含む組合せ物
WO2013105088A1 (en) Combination therapy for the treatment of cancer
JP2019517587A5 (cg-RX-API-DMAC7.html)
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
US20240398809A1 (en) Treatment of alopecia areata
EP4580631A1 (en) Dosage regimens of estrogen receptor degraders
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
CN104039148A (zh) 组合als疗法
TW202207942A (zh) 包含craf抑制劑的治療組合
EP4106756A1 (en) Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
JP2020516663A5 (cg-RX-API-DMAC7.html)
US8765720B2 (en) Combination therapy for the treatment of multiple myeloma
JP2006508118A5 (cg-RX-API-DMAC7.html)
JP2024502821A5 (cg-RX-API-DMAC7.html)
US11406627B2 (en) Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
JP2005526022A5 (ja) 関節リウマチの処置
US11179395B2 (en) Treating melanoma with mebendazole and a mitogen-activated kinase inhibitor
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
Weiss et al. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial